Semaglutide peptide treatment: Peptide Empire’s review

GLP-1 and appetite

Semaglutide copies the action of GLP-1, a hormone released by the gut. It helps prompt insulin release when blood sugar is high, reduces inappropriate glucagon release, slows stomach emptying and acts on brain circuits involved in appetite. Chemical changes protect the peptide from rapid breakdown and let it bind albumin, a protein in blood, extending its action.

The appetite story is often reduced to food sitting in the stomach. Brain signalling matters too. I think that broader account makes better sense of why hunger, fullness and food intake all appear in the discussion. The semaglutide safety review also shows the uncomfortable overlap: effects on the digestive system can become the reason treatment stops.

STEP 1: weight change

In STEP 1, 1,961 adults with overweight or obesity without diabetes were followed for 68 weeks. Mean body-weight change was -14.9% with semaglutide and -2.4% with placebo. These were average changes during a trial with accompanying care.

That is a substantial result. I give the programme credit for putting the weight claim through a large randomized comparison. The number still describes a group: an individual’s weight change, tolerability and reasons for stopping can differ.

Weight also changes after treatment ends. Some lost weight may be muscle. After stopping treatment, weight may come back. Those issues matter when the ambition shifts from a trial’s weight endpoint to living with treatment over time.

SELECT cardiovascular outcomes; FLOW kidney outcomes

The SELECT cardiovascular-outcomes trial enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo. Established heart disease was central to that question.

FLOW studied 3,533 people with type 2 diabetes and chronic kidney disease. Its combined primary outcome included kidney failure, at least a 50% decline in estimated kidney filtration, or death from kidney or cardiovascular causes. The result favoured semaglutide.

I credit SELECT and FLOW with giving the field’s expanding ambitions a convincing clinical shape. For healthy readers, extending the results to general organ protection would outrun the populations actually studied. The studied populations do much of the work in those sentences.

Semaglutide compared with tirzepatide

A later head-to-head trial in 751 adults with obesity compared tirzepatide with semaglutide. At 72 weeks, mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. Tirzepatide produced greater average weight loss in that comparison.

In SURMOUNT-5, I accept the winner of the weight comparison without appointing a champion of every possible outcome. The trial answered a weight question. SELECT and FLOW answered cardiovascular and kidney questions in their respective populations. Keeping those results distinct leaves a more useful account of both success and limitation.

Side effects and safety

The dedicated review of semaglutide safety describes nausea, vomiting, diarrhea and constipation as dominant adverse effects, generally transient and mild to moderate in the reviewed trials. Digestive intolerance can still be substantial enough to stop treatment. Gallbladder disease, including gallstones, is an identified risk.

Pancreatitis is a warning for this drug class. Pancreatic and thyroid cancer questions remain unresolved in the human evidence discussed by the review because events were uncommon. The boxed thyroid warning comes from rodent findings; it includes a contraindication for a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Rapid improvement in blood sugar can also worsen existing diabetic retinopathy, the eye damage associated with diabetes.

Stories about quieter thoughts of food, reduced cravings, sulfur-smelling burps, heartburn or fatigue add another layer. Those are anecdotal accounts rather than clinical evidence. They can describe the texture of an experience, but cannot establish how often an effect occurs or what caused it.

Formulations and approval

Approved semaglutide medicines have specified uses and formulations. The trials concern the medicine and population tested. A pharmacy-mixed product or research material with the same ingredient name does not automatically inherit those findings.

The favourable benefit–risk assessment in type 2 diabetes in the safety review also has a defined context. It leaves room for contraindications, adverse effects and a different balance for another person. The clinical programme earns my admiration by asking several particular questions. A sweeping claim about “semaglutide peptide treatment” would make that work less clear.